Virtual CME Program
Diabesity: Confronting the Dual Epidemic of Diabetes and Obesity
This session will delve into the intersection of obesity and type 2 diabetes mellitus (T2DM). Learners will explore strategies for glycemic and weight management, cardiorenal protection, and cardiovascular risk mitigation, with an emphasis on the latest guidelines for managing T2DM and providing holistic care.
CME/CE Information
0 Credits - Not for CME/CE Credit
Release Date: 5/16/2024
Expiration Date: 7/15/2024
Faculty
Learning Objectives
- Examine the relationship between type 2 diabetes mellitus (T2DM) and obesity and the therapeutic benefits of sustained weight loss on the long-term health risks of both conditions
- Discuss a holistic integrated approach to the management of T2DM, obesity, and other comorbid conditions
- Consider recent guideline recommendations for T2DM management, which stratify therapies according to their likelihood of achieving both glycemic and weight loss goals
- Examine the evidence for glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors for cardiorenal protection in T2DM and obesity
Faculty
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor
Assistant Dean for Culture & Community Education
Executive Director, UC Irvine Program in Medical Education for the Latino Community UC Irvine School of Medicine
Irvine, CA
Disclosures
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Charles Vega, MD, FAAFP: Consultant for Boehringer Ingelheim.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.